Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...

Mirum Pharmaceuticals, Inc. shows strong growth with a 43% revenue jump and promising pipeline assets. Click here for my ...

Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Operator: Hello, and welcome to Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update. My name is Elliot, and I’ll be your coordinator today.

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 7,489 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42. ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

FOSTER CITY, Calif. - Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reported fourth quarter earnings that fell short of analyst expectations, sending its stock down 4.4% in after-hours trading. The ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reported Q1 EPS of ($1.17), $0.17 better than the analyst estimate of ($1.34). Revenue ...

Luke Herrmann; Analyst; Robert W. Baird & Co., Inc. Hello, and welcome to Mirum Pharmaceuticals reports fourth quarter and year-end 2024 financial results and provides business update. My name is ...